Primary cutaneous peripheral T-cell lymphoma, not otherwise specified (pcPTCL-NOS) — a heterogeneous and rare category of primary cutaneous T-cell lymphomas (CTCLs) that present primarily in the skin without evidence of extracutaneous disease at diagnosis but do not fulfill the diagnostic criteria for any of the specifically defined primary cutaneous T-cell lymphoma entities recognized by the WHO-EORTC classification (mycosis fungoides, Sézary syndrome, primary cutaneous CD30+ lymphoproliferative disorders, subcutaneous panniculitis-like T-cell lymphoma, or extranodal NK/T-cell lymphoma, nasal type), representing approximately 2–4% of all primary CTCLs — exhibiting a CD4+ T-cell phenotype in most cases (cytotoxic CD8+ variants also recognized, with worse prognosis) with aberrant T-cell immunophenotype (loss of pan-T-cell antigens CD2, CD3, CD5, or CD7 common), TCR gene rearrangement demonstrating T-cell clonality, EBV-negative, variable expression of CD30 (below the threshold for primary cutaneous anaplastic large cell lymphoma classification), and frequent expression of TFH (T follicular helper) markers (PD-1, CXCL13, ICOS, CD10, BCL6) in a subset — presenting with solitary, multifocal, or generalized erythematous plaques, tumors, or nodules without the epidermotropism characteristic of mycosis fungoides — carrying an aggressive behavior with poor prognosis distinguishing pcPTCL-NOS from indolent CTCLs (5-year overall survival approximately 15–20% compared to >90% in classic mycosis fungoides), with a significant risk of extracutaneous dissemination (lymph node, bone marrow, visceral) over the disease course — requiring management with aggressive multiagent systemic chemotherapy (CHOP or CHOEP as initial therapy, similar to nodal PTCLs), consolidation with autologous or allogeneic stem cell transplant in eligible responding patients, involved-field radiation, and novel agents (brentuximab vedotin for CD30+ cases, romidepsin, pralatrexate, belinostat) for relapsed/refractory disease — is a disease where the dermatopathology platform delivering the aberrant T-cell immunophenotyping with pan-T-cell antigen loss and clonality analysis that diagnoses pcPTCL-NOS and excludes all defined CTCL entities, the systemic staging platform excluding extracutaneous dissemination to confirm primary cutaneous designation, the aggressive systemic chemotherapy platform managing CHOP/CHOEP infusion with toxicity monitoring, the stem cell transplant coordination platform managing ASCT or alloSCT consolidation in eligible patients, the novel agent platform managing targeted and epigenetic therapies for relapsed/refractory disease, and the long-term surveillance platform managing the high relapse risk and extracutaneous dissemination monitoring create technology platform requirements no generic oncology monitoring strategy was designed to address: pcPTCL-NOS platforms must simultaneously support dermatopathology workflows for comprehensive T-cell phenotyping and clonality analysis, systemic staging, aggressive multiagent chemotherapy administration, stem cell transplant coordination, novel agent therapy, and long-term relapse and extracutaneous dissemination surveillance. The technology platforms supporting pcPTCL-NOS care span EHR modules coordinating the multidisciplinary dermatology-dermatopathology-hematology-oncology-radiation oncology workup, dermatopathology systems managing T-cell phenotyping and clonality analysis, staging platforms for extracutaneous disease exclusion, aggressive systemic chemotherapy infusion management systems, stem cell transplant coordination platforms, novel agent therapy management systems, and long-term surveillance platforms.
pcPTCL-NOS technology platforms — whether supporting academic dermatology-hematology programs diagnosing pcPTCL-NOS through the characteristic combination of primary cutaneous presentation, absence of systemic disease at staging, aberrant T-cell immunophenotype with pan-T-cell antigen loss, T-cell clonality by TCR gene rearrangement, and careful exclusion of all specifically defined CTCL entities; dermatopathology platforms performing comprehensive T-cell IHC panels (CD2, CD3, CD4, CD5, CD7, CD8, CD20, CD25, CD30, CD45RO, CD56, CD57, TIA-1, granzyme B, perforin, PD-1, CXCL13, ICOS, CD10, BCL6, FOXP3, TCF1, GATA3, TBX21, EBV-LMP1/EBER), TCR gene rearrangement PCR and next-generation sequencing for T-cell clonality, T-cell receptor flow cytometry immunophenotyping, FISH for chromosomal abnormalities, gene expression profiling in specialized programs, and Ki-67 proliferation index; systemic staging platforms coordinating CT chest-abdomen-pelvis or PET/CT, bone marrow biopsy with T-cell immunohistochemistry, peripheral blood flow cytometry, LDH and beta-2-microglobulin, and exclusion of peripheral blood large granular lymphocyte leukemia; aggressive systemic chemotherapy platforms managing CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) or CHOEP (with etoposide) infusion with complete blood count monitoring, GCSF administration, neutropenic fever management, and treatment response assessment after each cycle; stem cell transplant coordination platforms managing ASCT (carmustine-etoposide-cytarabine-melphalan or BEAM conditioning) or alloSCT for eligible patients with donor search, HLA typing, conditioning regimen administration, and engraftment monitoring; or novel agent therapy platforms managing brentuximab vedotin (anti-CD30 ADC) for CD30+ relapsed/refractory cases, romidepsin (HDAC inhibitor), pralatrexate, or belinostat with toxicity monitoring and response assessment — must maintain the availability and performance standards that an aggressive primary cutaneous T-cell lymphoma with 15–20% five-year overall survival requiring urgent multiagent systemic chemotherapy and SCT consolidation demands. This guide explains why pcPTCL-NOS tech platforms need dedicated monitoring, what components to monitor, and how to build a monitoring strategy that matches the aberrant T-cell biology, aggressive clinical behavior, systemic staging requirements, multiagent chemotherapy toxicity monitoring, SCT coordination, and long-term extracutaneous dissemination surveillance obligations of modern pcPTCL-NOS management.
Why pcPTCL-NOS Tech Platforms Require Specialized Monitoring Attention
pcPTCL-NOS management demands coordination across dermatology, dermatopathology, hematology-oncology, radiation oncology, and stem cell transplant programs, with the dermatopathological T-cell phenotyping and clonality analysis as the diagnostic foundation, systemic staging as the essential disease-defining workup, aggressive multiagent chemotherapy as the first-line treatment, and SCT consolidation as the potentially curative consolidation modality for eligible responding patients.
Dermatopathology platforms deliver the aberrant T-cell immunophenotyping that diagnoses pcPTCL-NOS. The diagnosis of pcPTCL-NOS is fundamentally a diagnosis of exclusion — requiring affirmative demonstration of aberrant T-cell immunophenotype with pan-T-cell antigen loss and T-cell clonality, while systematically excluding all specifically defined CTCL entities. The critical diagnostic distinction between pcPTCL-NOS (aggressive, 15–20% five-year OS, requiring CHOP/CHOEP chemotherapy) and indolent CTCLs — mycosis fungoides (>90% five-year OS with skin-directed therapy), primary cutaneous anaplastic large cell lymphoma (pcALCL, excellent prognosis with spontaneous regression), or primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder (indolent, often resolves without treatment) — requires accurate comprehensive T-cell phenotyping and is the single most consequential diagnostic determination affecting treatment intensity. Platforms managing T-cell IHC panel result routing, TCR gene rearrangement result routing, T-cell flow cytometry result routing, TFH marker panel result routing, EBV testing result routing, and dermatopathology-hematology interdisciplinary conference scheduling cannot fail during diagnostic workup. Monitor dermatopathology platforms during business and urgent-case hours.
Systemic staging platforms confirm primary cutaneous designation and exclude extracutaneous dissemination. The designation of PRIMARY cutaneous PTCL-NOS requires the exclusion of nodal PTCL-NOS with secondary skin involvement — which would require identical pathology in systemic disease and carry different staging and prognostic implications — through CT chest-abdomen-pelvis or PET/CT, bone marrow biopsy, peripheral blood flow cytometry, and LDH assessment. PET/CT is particularly valuable given the aggressive biology of pcPTCL-NOS and its propensity for extracutaneous dissemination. The staging conclusion directly determines whether a patient has primary cutaneous disease (treatable with CHOP/CHOEP in the setting of CTCL programs) or systemic PTCL with skin involvement (treatable with systemic PTCL programs). Platforms managing PET/CT or CT result routing, bone marrow biopsy result routing, peripheral blood flow cytometry result routing, LDH result routing, and staging report integration confirming primary cutaneous designation cannot fail during staging workup. Monitor staging platforms at 2-minute intervals during business hours.
Aggressive systemic chemotherapy platforms manage the primary treatment modality. CHOP (cyclophosphamide 750 mg/m², doxorubicin 50 mg/m², vincristine 1.4 mg/m², prednisone 100 mg/day × 5 days, every 21 days) or CHOEP (with etoposide 100 mg/m² added) administered for 6–8 cycles with G-CSF growth factor support represents the standard first-line treatment for pcPTCL-NOS. Platforms managing chemotherapy order verification, CBC result routing for cycle eligibility assessment, GCSF administration documentation, neutropenic fever management and empiric antibiotic administration, cardiotoxicity monitoring with echocardiography (anthracycline cumulative dose), peripheral neuropathy monitoring (vincristine), treatment response assessment with PET/CT or CT after cycles 2–4 and at completion, and dose modification documentation cannot fail during active chemotherapy. Monitor aggressive systemic chemotherapy platforms at 2-minute intervals during active treatment phases.
Stem cell transplant coordination platforms support potentially curative consolidation. ASCT consolidation in first complete remission is recommended for eligible pcPTCL-NOS patients given the high relapse rate — with alloSCT considered for relapsed/refractory disease or high-risk features. ASCT coordination requires stem cell mobilization (GCSF ± plerixafor), apheresis collection with CD34+ quantification, high-dose conditioning (BEAM: carmustine, etoposide, cytarabine, melphalan), infusion and engraftment monitoring (ANC ≥ 0.5 × 10⁹/L), and post-ASCT infectious prophylaxis management. AlloSCT adds donor search, HLA typing, donor source selection (MSD, MUD, haplo), and graft-versus-lymphoma effect monitoring. Platforms managing mobilization protocol documentation, apheresis collection records, conditioning regimen administration, engraftment CBC result routing, post-transplant infectious complication management, and transplant program-dermatology coordination cannot fail during active transplant phases. Monitor SCT platforms at 2-minute intervals during active transplant.
Novel agent therapy platforms manage relapsed/refractory disease. Brentuximab vedotin (BV, anti-CD30 ADC, for CD30+ cases — CD30 expression must be confirmed by IHC), romidepsin (histone deacetylase inhibitor), pralatrexate, belinostat, and clinical trial agents represent the salvage landscape for relapsed/refractory pcPTCL-NOS. BV toxicity monitoring (peripheral neuropathy, pulmonary toxicity, hepatotoxicity), romidepsin toxicity monitoring (QTc prolongation, nausea), pralatrexate toxicity monitoring (mucositis, cytopenias), and response assessment with repeat staging are core platform functions. Platforms managing targeted and novel agent order management, pre-treatment CD30 status confirmation, QTc monitoring result routing, peripheral neuropathy assessment, and response assessment imaging result routing cannot fail during novel agent therapy. Monitor novel agent therapy platforms during business hours.
What to Monitor on a pcPTCL-NOS Tech Platform
Dermatopathology and T-Cell Immunophenotyping
Monitor T-cell IHC panel result routing (CD2, CD3, CD4, CD5, CD7, CD8, CD20, CD25, CD30, CD45RO, CD56, CD57, TIA-1, granzyme B, perforin, PD-1, CXCL13, ICOS, CD10, BCL6, FOXP3), TCR gene rearrangement PCR and NGS result routing for T-cell clonality (TCRβ, TCRγ), T-cell flow cytometry immunophenotyping with aberrant phenotype documentation (pan-T-cell antigen loss), TFH marker panel result routing (PD-1, CXCL13, ICOS, CD10, BCL6) for subset characterization, EBV testing result routing (LMP1 IHC and EBER ISH), Ki-67 proliferation index documentation, FISH chromosomal abnormality result routing, gene expression profiling result routing when available, exclusion checklist documentation for defined CTCL entities (MF criteria, pcALCL criteria, SPTCL criteria), and dermatopathology-hematology interdisciplinary conference scheduling during business and urgent-case hours.
Systemic Staging and Primary Cutaneous Designation Confirmation
Monitor PET/CT result routing with FDG-avid lesion quantification (cutaneous only versus extracutaneous lymphadenopathy, visceral disease), CT chest-abdomen-pelvis result routing when PET/CT unavailable, bone marrow biopsy result routing (H&E, T-cell IHC panel, T-cell flow cytometry, TCR clonality concordance with skin), peripheral blood flow cytometry result routing for circulating PTCL cells, peripheral blood TCR clonality concordance assessment, LDH result routing, beta-2-microglobulin result routing, staging report integration confirming primary cutaneous designation, and staging-based IPI or PIT scoring documentation at 2-minute intervals during business hours.
CHOP/CHOEP Chemotherapy Administration and Toxicity Monitoring
Monitor chemotherapy order verification (CHOP: cyclophosphamide, doxorubicin, vincristine, prednisone; CHOEP: with etoposide addition), CBC result routing for cycle eligibility (ANC ≥ 1.0 × 10⁹/L, platelets ≥ 75 × 10⁹/L), G-CSF administration documentation and scheduling, neutropenic fever onset documentation with empiric antibiotic administration initiation, echocardiography result routing for anthracycline cumulative dose cardiotoxicity monitoring (LVEF assessment after 300 mg/m² cumulative doxorubicin), peripheral neuropathy assessment documentation (vincristine-related), renal function result routing for cyclophosphamide dose adjustment, dose modification documentation with rationale, mid-treatment response PET/CT result routing after cycles 2–4, end-of-treatment PET/CT or CT result routing for response classification (Lugano criteria), and dose intensity documentation at 2-minute intervals during active chemotherapy cycles.
Stem Cell Transplant Coordination (ASCT and AlloSCT)
Monitor ASCT mobilization protocol documentation (GCSF ± plerixafor dosing), apheresis session documentation with CD34+ cell quantification (target ≥ 2 × 10⁶ CD34+ cells/kg), BEAM conditioning regimen administration documentation (carmustine, etoposide, cytarabine, melphalan), stem cell infusion documentation with cell count and viability, daily CBC result routing during aplasia for ANC and platelet engraftment monitoring, post-transplant infection prophylaxis administration (antifungal, antiviral, antibacterial, PCP), engraftment confirmation documentation, alloSCT HLA typing result routing, donor search documentation (MSD, MUD, haplo), alloSCT conditioning regimen documentation, graft-versus-host disease assessment post-alloSCT, and chimerism testing result routing at 2-minute intervals during active transplant phases.
Novel Agent Therapy and Relapsed/Refractory Management
Monitor brentuximab vedotin order management with pre-treatment CD30 IHC confirmation (≥10% CD30 expression threshold), BV peripheral neuropathy grade assessment before each cycle, BV pulmonary toxicity monitoring (cough, dyspnea, chest imaging when indicated), romidepsin QTc monitoring (ECG before and 4 hours after first dose, baseline electrolyte monitoring), pralatrexate mucositis grade assessment with leucovorin and vitamin B12 supplementation documentation, belinostat hepatotoxicity monitoring, restaging imaging result routing after 2–4 cycles of novel agent therapy, clinical trial enrollment documentation and protocol compliance monitoring, and novel agent dose modification documentation during business hours.
Long-Term Surveillance and Extracutaneous Dissemination Monitoring
Monitor scheduled surveillance PET/CT or CT result routing for extracutaneous dissemination detection at defined intervals, dermatologic examination documentation for new or progressing skin lesions, serial photography for skin disease extent assessment, new lymphadenopathy documentation, B-symptom assessment (fever, night sweats, weight loss) as relapse indicators, bone marrow biopsy scheduling when systemic relapse is suspected, LDH trending as relapse biomarker, and hematology-oncology-dermatology coordination for relapse staging and salvage therapy planning during business hours.
Authentication and Clinical Identity
Monitor authentication at 1-minute intervals, 24/7. pcPTCL-NOS care requires simultaneous platform access across dermatology, dermatopathology, hematology-oncology, radiation oncology, stem cell transplant programs, and pharmacy, with CHOP/CHOEP chemotherapy requiring neutropenic fever management monitoring and SCT requiring continuous engraftment monitoring. Authentication failures during active chemotherapy cycles, neutropenic fever management, or SCT engraftment monitoring block the coordinated care team managing this aggressive primary cutaneous T-cell lymphoma.
SSL Certificates Across All Domains
Monitor SSL certificate expiry across patient portals, dermatopathology platforms, staging and imaging systems, systemic chemotherapy management environments, SCT coordination systems, novel agent therapy management platforms, and long-term surveillance systems.
HIPAA and Oncology Data Privacy Considerations
Primary cutaneous peripheral T-cell lymphoma, NOS technology platforms handle sensitive PHI including rare aggressive CTCL diagnoses with poor prognosis documentation, detailed dermatopathology reports with T-cell phenotyping and clonality analysis, systemic staging records including PET/CT, bone marrow biopsy, and peripheral blood flow cytometry, CHOP/CHOEP chemotherapy administration records with toxicity documentation, echocardiography records for anthracycline cardiotoxicity monitoring, ASCT and alloSCT procedure records, novel agent therapy records with peripheral neuropathy and cardiotoxicity documentation, and long-term surveillance records for extracutaneous dissemination. HIPAA Security Rule requirements for PHI availability and integrity apply across all platform components.
pcPTCL-NOS platforms carry distinctive privacy dimensions: the aggressive prognosis documentation (15–20% five-year OS) requires careful communication management and patient-sensitive PHI handling. The dermatopathology exclusion checklist — documenting that every defined CTCL entity was considered and excluded — creates a differential diagnosis PHI record that is both clinically and medicolegally significant. AlloSCT platforms add donor PHI with HLA typing records. Novel agent CD30 biomarker testing results may influence insurance eligibility for brentuximab vedotin (covered indication-specific), requiring careful biomarker PHI management. Serial skin photography for disease extent documentation is body-surface PHI requiring strict access controls. Availability monitoring provides operational documentation relevant to HIPAA Security Rule administrative safeguard compliance.
Alerting Strategy for pcPTCL-NOS Tech Platforms
Immediate alert during active CHOP/CHOEP chemotherapy cycles: Chemotherapy management platforms during active infusion and post-infusion neutropenic nadir periods (days 10–14 post-CHOP), where neutropenic fever management requires immediate platform access.
Immediate alert during active ASCT and alloSCT phases: Stem cell transplant coordination platforms during conditioning, stem cell infusion, and engraftment monitoring phases.
Immediate alert during active staging workup: Staging platforms during initial diagnosis when aggressive treatment strategy depends on primary cutaneous designation confirmation.
Sustained-failure alert (10–15 minutes): Dermatopathology, novel agent therapy, long-term surveillance, and authentication platforms. Alert when failures persist beyond a single workflow cycle.
30-day advance warning: SSL certificates across all domains.
Vigilmon's multi-region monitoring confirms pcPTCL-NOS platform availability from the geographies where major CTCL-hematology programs — US academic dermatology-oncology centers, European CTCL reference programs, and Asian programs with cutaneous T-cell lymphoma expertise — access the system.
Status Page for pcPTCL-NOS Care Team Communication
A real-time status page gives pcPTCL-NOS program coordinators, dermatopathologists delivering T-cell phenotyping and clonality results, hematology-oncologists managing CHOP/CHOEP chemotherapy and SCT coordination, dermatologists managing skin disease assessment and biopsy, radiation oncologists administering involved-field radiation, SCT program coordinators managing ASCT and alloSCT logistics, pharmacy teams managing chemotherapy and novel agent orders, and clinic coordinators immediate platform visibility without requiring inbound IT support contact. During a chemotherapy management platform outage, a status page enables simultaneous activation of manual CBC result communication, telephone-based neutropenic fever management coordination, and manual dose modification documentation.
Include the status page URL in CHOP/CHOEP infusion downtime procedures, SCT management contingency plans, neutropenic fever management backup workflows, and staging platform downtime procedures.
Vigilmon Setup for pcPTCL-NOS Tech Platforms
A practical starting configuration:
| Monitor | Check Interval | Alert Channel | |---------|----------------|---------------| | Authentication | 1 min | Slack + PagerDuty (24/7) | | CHOP/CHOEP chemotherapy (active cycles + nadir) | 2 min | Slack + PagerDuty (active cycles) | | ASCT / alloSCT (active transplant phases) | 2 min | Slack + PagerDuty (active transplant) | | Systemic staging (active staging workup) | 2 min | Slack + PagerDuty (active staging) | | Dermatopathology / T-cell IHC / TCR clonality | 2 min | Slack (business hours) | | Novel agent therapy (brentuximab vedotin / romidepsin) | 2 min | Slack (business hours) | | Long-term surveillance / PET-CT / extracutaneous monitoring | 2 min | Slack (business hours) | | Echocardiography / cardiotoxicity monitoring | 2 min | Slack (business hours) | | Patient communication portal | 2 min | Slack (business + evening hours) | | SSL: all domains | Daily | Email (30-day warning) |
Getting started:
- Create a free account at vigilmon.online
- Add authentication at 1-minute intervals with 24/7 alerting
- Configure CHOP/CHOEP chemotherapy platforms with immediate alerting during active infusion cycles and the neutropenic nadir period (days 10–14 post-cycle)
- Configure ASCT and alloSCT coordination platforms with immediate alerting during conditioning, infusion, and engraftment monitoring phases
- Add staging platforms with immediate alerting during initial workup when primary cutaneous designation is being established
- Configure dermatopathology platforms with business-hours alerting for T-cell IHC panel, TCR gene rearrangement, and TFH marker result routing
- Add novel agent therapy management with business-hours alerting for brentuximab vedotin peripheral neuropathy and romidepsin QTc monitoring
- Configure long-term surveillance with business-hours alerting for PET/CT extracutaneous dissemination monitoring
- Add echocardiography with business-hours alerting for anthracycline cumulative dose cardiotoxicity monitoring
- Enable SSL certificate monitoring across all clinical, patient-facing, and laboratory platform domains
- Add the status page URL to CHOP/CHOEP infusion, SCT management, staging, and neutropenic fever management downtime procedures
Conclusion
Primary cutaneous peripheral T-cell lymphoma, NOS technology platforms are embedded at a clinically critical intersection of rare aggressive CTCL diagnosis, urgently required treatment initiation, and potentially curative SCT consolidation: the dermatopathology platform must deliver the comprehensive T-cell immunophenotyping with pan-T-cell antigen loss, TCR gene rearrangement clonality, and the systematic exclusion of all defined CTCL entities that diagnoses pcPTCL-NOS and — critically — distinguishes it from indolent CTCLs requiring only skin-directed therapy, because a misdiagnosis that delays CHOP/CHOEP in pcPTCL-NOS allows rapid extracutaneous dissemination in a disease with 15–20% five-year survival; staging platforms must confirm primary cutaneous designation by excluding nodal PTCL with secondary skin involvement and extracutaneous dissemination; aggressive chemotherapy platforms must support CHOP/CHOEP infusion with continuous neutropenic fever management and anthracycline cardiotoxicity monitoring; SCT coordination platforms must execute ASCT consolidation in first complete remission for eligible patients — the potentially curative intervention that most improves outcomes; novel agent therapy platforms must manage brentuximab vedotin, romidepsin, pralatrexate, and belinostat for the relapsed/refractory majority; and long-term surveillance platforms must maintain availability for the extracutaneous dissemination monitoring that defines the trajectory of this aggressive primary cutaneous T-cell lymphoma.
Uptime monitoring gives pcPTCL-NOS tech teams the detection capability to identify failures within seconds across dermatopathology, systemic staging, CHOP/CHOEP chemotherapy management, ASCT and alloSCT coordination, novel agent therapy, and long-term surveillance chains, trigger immediate clinical downtime procedures, and demonstrate to pcPTCL-NOS programs, dermatopathology services, hematology-oncology teams, stem cell transplant programs, radiation oncology teams, and compliance teams that the platform's operational reliability matches the aggressive T-cell biology, diagnostic exclusion complexity, multiagent chemotherapy toxicity monitoring demands, SCT coordination requirements, and extracutaneous dissemination surveillance obligations of one of dermatology-oncology's most clinically urgent rare cutaneous lymphomas.
Start monitoring your primary cutaneous peripheral T-cell lymphoma, NOS care tech platform for free at vigilmon.online — HTTP/HTTPS monitoring, multi-region consensus alerting, SSL certificate monitoring, automatic status page, Slack and webhook alerts. No agent required. No credit card.
Tags: #monitoring #primaryCutaneousPTCL #pcPTCLNOS #cutaneousTCellLymphoma #CTCL #PTCL #peripheralTCellLymphoma #aggressiveLymphoma #dermatopathology #TCRclonality #TFH #CHOP #CHOEP #ASCT #alloSCT #brentuximabVedotin #romidepsin #neuroOncology #hematologyOncology #stemCellTransplant #healthtech #digitalhealth #uptime #hipaa #cancertech #sre